Impact of the non-cellular tumor microenvironment on metastasis: Potential therapeutic and imaging opportunities

Journal of Cellular Physiology

Volumn 213, Issue 2, 2007, Pages 391-402

  Cretu, Alexandra ^a   Brooks, Peter C ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FIBRINOGEN; REGULATOR PROTEIN; SCLEROPROTEIN; VITRONECTIN;

BINDING SITE; CANCER INVASION; CELL ADHESION; CELL INTERACTION; CELL JUNCTION; CELL TYPE; COMPLEX FORMATION; EXTRACELLULAR MATRIX; EXTRAVASATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR GENETICS; MOLECULAR INTERACTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; SHORT SURVEY; SOLID STATE; TUMOR CELL;

ANIMALS; CELL ADHESION; CELL COMMUNICATION; CELL TRANSFORMATION, NEOPLASTIC; COLLAGEN; EPITOPES; EXTRACELLULAR MATRIX; FIBRINOGEN; HUMANS; LAMININ; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PEPTIDES; PHENOTYPE; VITRONECTIN;

EID: 34848863979     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21222     Document Type: Short Survey

References (127)

1. Akakura N, Hoogland C, Takada Y, Saegusa J, Ye X, Liu FT, Cheung AT, Takada Y. 2006. The COOH-terminal globular domain of fibrinogen γ chain suppresses angiogenesis and tumor growth. Cancer Res 66:9691-9697.
2. Akalu A, Brooks PC. 2005. Matrix, extracellular and interstitial. In: Meyers RA, editor. Encyclopedia of molecular cell biology and molecular medicine. 2nd edition. Weinheim: Wiley-VCH Verlag GmbH & Co. KgaA. pp 47-79.
3. Akalu A, Brooks PC. 2007. Integrins, adhesion, and coadhesion inhibitors in angiogenesis. In: Davis DN, editor. Anti-angiogeneic cancer therapy. London: Taylor and Francis. pp 273-293.
4. Akalu A, Cretu A, Brooks PC. 2005. Targeting integrins for the control of tumour angiogenesis. Expert Opin Investig Drugs 14:1475-1486.
5. Akalu A, Roth M, Caunt M, Policarpio D, Liebes L, Brooks PC. 2007. Inhibition of angiogenesis and tumor metastasis by targeting a matrix immobilized cryptic extracellular matrix epitope in laminin. Cancer Res 67:4353-4363.
6. Al-Mhendi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ. 2000. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: A new model for metastasis. Nat Med 6:100-102.
7. Ben-Baruch A. 2006. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 25:357-371.
8. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-744.
9. Bloemendal HJ de Boer HC, Koop EA, van Dongen AJ, Goldschmeding R, Landman WJ, Logtenberg T, Gebbink MF, Voest EE. 2004. Activated vitronectin as a target for anticancer therapy with human antibodies. Cancer Immunol Immunother 53:799-808.
10. Boo YJ, Park JM, Kim J, Chae YS, Min BW, Um JW, Moon HY. 2007. L1 expression as a maker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol 14:1703-1711.
11. Bornstein P, Sage EH. 2002. Matricellular proteins: Extracellular modulators of cell function. Curr Opin Cell Biol 14:608-616.
12. Brodsky SV, Merks RM, Mendelev N, Goo C, Chen J. 2006. Glycated collagen I (GC) impairs angiogenesis in vitro - A study using innovative chamber for cell research. Diabetes Res Clin Pract 76:463-467.
13. Brooks PC. 2002. Cooperative integrin interactions in the regulation of tumor metastasis. In: Welch DR, editor. Cancer metastasis-related genes. Netherlands: Kluwer Academic Publishers. pp 65-87.
14. Brooks PC, Strömblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA. 1996. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85:683-693.
15. Brooks PC, Silietti S, von Schalscha TL, Friedlander M, Cheresh DA. 1998. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92:391-400.
16. Brown E, McKee T, diTomaso E, Pluen A, Seed B, Boucher Y, Jain RK. 2003. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 9:796-800.
17. Carmeliet P. 2000. Gene targeting and gene transfer to unravel the molecular basis of the formation and disorders of blood vessels. Verh K Acad Geneeskd Belg 62:31-68.
18. Christiansen JJ, Rajasekaran AK. 2006. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66:8319-8326.
19. Christofori G. 2006. New signals from the invasive front. Nature 441:444-450.
20. Colorado PC, Torre A, Kamphaus G, Maeshima Y, Hopfer H, Takahashi K, Volk R, Zamborsky ED, Herman S, Sarkar PK, Ericksen MB, Dhanabal M, Simons M, Post M, Kufe DW, Weichselbaum RR, Sukhatme VP, Kalluri R. 2000. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 60:2520-2526.
21. Côme C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C, Savagner P. 2006. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res 12:539S-5402.
22. Cretu A, Roth JM, Caunt M, Akalu A, Policarpio D, Formenti A, Gagne P, Liebes L, Brooks PC. 2007. Disruption of endothelial cell interactions with the novel HUI77 cryptic collagen epitope inhibits angiogenesis. Clin Cancer Res 13:3068-3078.
23. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploung M, Romer J. 2005. Plasminogen activation and cancer. Throm Haemost 93:675-681.
24. Davis GE, Bayless KJ, Davis MJ, Meininger GA. 2000. Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am J Pathol 156:1489-1498.
25. Decock J, Paridaens R, Cufer T. 200S. Proteases and metastasis: Clinical relevance nowadays? Curr Opin Oncol 17:545-550.
26. Demou ZN, Awad M, McKee T, Perentes JY, Wang X, Munn LL, Jain RK, Boucher Y. 2005. Lack of telopeptides in fibrillar collagen I promotes the invasion of metastatic breast tumor cell line. Cancer Res 65:5674-5682.
27. Deryugina EI, Quigley JP. 2006. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25:9-34.
28. Dumin JA, Dickeson SK, Stricker TP, Bhattacharyya-Pakrasi M, Roby JD, Santoro SA, Parks WC. 2001. Pro-collagenase-1 (matrix metalloproteinase-1) bind the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen. J Biol Chem 276:29368-29374.
29. Eccles SA, Welch DR. 2007. Metastasis: Recent discoveries and novel treatment strategies. Lancet 369:1742-1757.
30. Filippov S, Koenig GC, Chun TH, Hotary KB, Ota I, Bugge TH, Roberts JD, Fay WP, Birkedal-Hansen H, Holmbeck K, Sabeh F, Alen ED, Weiss SJ. 2005. MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. J Exp Med 202:663-671.
31. 2+. Eur J Cell Biol 86:143-160.
32. Freimark B, Clark D, Pernasetti F, Nickel J, Myszka D, Baeuerle PA, Van Epps D. 2005. Targeting of humanized antibody D93 to sites of angiogenesis and tumor growth by binding to multiple epitopes on denatured collagens. Mol Immunol 44:3741-3750.
33. Friedl P, Wolf K. 2003. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat Rev Cancer 3:362-374.
34. Gagne P, Tihonov N, Li X, Glaser J, Qiao J, Silberstein M, Yee H, Gagne E, Brooks PC. 2005. Temporal exposure of cryptic collagen epitopes within ischemic muscle during hindlimb reperfusion. Am J Pathol 167:1449-1459.
35. Givant-Horwitz V, Davidson B, Reich R. 2005. Laminin-induced signaling in tumor cells. Cancer Lett 223:1-10.
36. Goldfinger LE, Stack MS, Jones JC. 1998. Processing of laminin-5 and its functional consequences: Role of plasmin and tissue-type plasminogen activator. J Cell Biol 141:255-265.
37. Gupta GP, Massague J. 2006. Cancer metastasis: Building a framework. Cell 127:679-695.
38. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A, Kalluri R. 2003. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphav beta3 integrin. Cancer Cell 3:589-601.
39. Hehlgans S, Haase M, Cordes N. 2007. Signalling via integrins: Implications for cell survival and anticancer strategies. Biochim Biophys Acta 1775:163-180.
40. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, Postovit LM. 2007. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Med 7:246-225.
41. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. 2006. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastases. Nature Cell Biol 8:1369-1375.
42. Hocking DC, Kowalski K. 2002. A cryptic fragment from fibronectin's III1 module localizes to lipid rafts and stimulates cell growth and contractility. J Cell Biol 158:175-184.
43. Hotary KB, Allen EDM, Brooks PC, Datta NS, Long MW, Weiss SJ. 2003. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114:33-45.
44. Huber MA, Kraut N, Beug H. 2005. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548-558.
45. Iwamoto Y, Robey FA, Graf J, Sasaki M, Kleinman HK, Yamada Y, Martin GR. 1987. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 238:1132-1134.
46. Janes SM, Watt FM. 2004. Switch from αvβ5 to αvβ6 integrin expression protects squamous cell carcinomas from anoikis. J Cell Biol 166:419-431.
47. Jo N, Ju M, Nishijima K, Robinson GS, Adamis AP, Shima DT, Mailhos C. 2006. Inhibitory effect of an antibody to cryptic collagen IV epitopes on choroidal neovascularization. Mol Vis 12:1243-1249.
48. Kakinuma T, Hwant ST. 2006. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 79:639-651.
49. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R. 2000. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275:1209-1215.
50. Kaplan RN, Psaila B, Lyden B, 2006. Bone marrow cells in the 'pre-metastatic niche': Within bone and beyond. Cancer Metastasis Rev 25:521-529.
51. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D. 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820-827.
52. Karagiannis ED, Popel AS. 2007. Identification of novel short peptides derived from the α4, α5, and α6 fibrils of type IV collagen with anti-angiogenic properties. Biochem Biophys Res Commun 354:434-439.
53. Kaspar M, Zardi L, Neri D. 2006. Fibronectin as target for tumor therapy. Int J Cancer 118:1331-1339.
54. Kaspar M, Trachsel E, Neri D. 2007. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and angiogenesis. Cancer Res 67:4940-4948.
55. Kato R, Ishikawa T, Kamiya S, Oguma F, Ueki M, Goto S, Naamura H, Katayma T, Fukai F. 2002. A new type of antimetastatic peptide derived from fibronectin. Clin Cancer Res 8:2455-2462.
56. Kauppila S, Stenbäck F, Risteli J, Jukkola A, Risteli L. 1998. Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J Pathol 186:262-268.
57. Kawaguchi T, Yamashita Y, Kanamori M, Endersby R, Bankiewicz KS, Baker SJ, Bergers G, Pieper RO. 2006. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res 66:11331-11340.
58. Khazenzon NM, Ljubimov AV, Lakhter AJ, Fujita M, Fujiwara H, Sekiguchi K, Sorokin LM, Petäjäniemi N, Virtanen I, Black KL, Ljubimova JY. 2003. Antisense inhibition of laminin-8 expression reduces invasion of human gliomas in vitro. Mol Cancer Ther 2:985-993.
59. Kim WH, Lee BL, Kim DK, Kleinman HK. 1999. Laminin-1-adherent cancer cells show increased proliferation and decreased apoptosis in vivo. Anticancer Res 19:3067-3071.
60. Kopfstein L, Christofori G. 2006. Metastasis: Cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci 63:449-468.
61. Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. 2000. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 148:615-624.
62. Kuratomi Y, Nomizu M, Nielsen PK, Tanaka K, Song SY, Kleinman HK, Yamada Y. 1999. Identification of metastasis-promoting sequences in the mouse laminin alpha 1 chain. Exp Cell Res 249:386-395.
63. Labat-Robert J. 2002. Fibronectin in malignancy. Semin Cancer Biol 12:187-195.
64. Larsen M, Artym VV, Green JA, Yamada KM. 2006. The matrix reorganized: Extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol 18:463-471.
65. Lo KM, Lan Y, Lauder S, Zhang J, Brunkhorst B, Qin G, Verma R, Courtenay-Luck N, Gillies SD. 2007. huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. Cancer Immunol Imunother 56:447-457.
66. Lobov IB, Brooks PC, Lang RA. 2002. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 99:11205-11210.
67. Lord ST. 2007. Fibrinogen and fibrin: Scaffold proteins in hemostasis. Curr Opin Hematol 14:236-241.
68. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE, Kalluri R. 2000. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 275:21340-21348.
69. Marinkovich MP. 2007. Tumour microenvironment: Laminin 332 in squamous-cell carcinoma. Nat Rev Cancer 7:370-380.
70. Menrad A, Menssen HD. 2005. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets 9:491-500.
71. Minor KH, Peterson CB. 2002. Plasminogen activator inhibitor type I promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix. J Biol Chem 277:10337-10345.
72. Miura S, Kamiya S, Saito Y, Wada S, Hayashi R, Taira J, Kodama H, Yajima H, Ueki M, Fukai F. 2007. Antiadhesive sites present in fibronectin type III-like repeats of human plasma fibronectin. Biol Pharm Bull 30:891-897.
73. Mohamed MM, Sloane BF. 2006. Cysteine cathepsins: Multifunctional enzymes in cancer. Nat Rev Cancer 6:764-775.
74. Mongiat M, Sweeney SM, San Antonio JD, Fu J, Iozzo RV. 2003. Endorepellin, a novel inhibitor of angiogenesis derived from the C-terminus of perlecan. J Biol Chem 278:4238-4249.
75. Montgonmery AM, Reisfelf RA, Cheresh DA. 1994. Integrin alpha v beta 3 rescues cells from apoptosis in three-dimensional dermal collagen. Proc Natl Sci U S A 91:8856-8860.
76. Mosesson MW. 2005. Fibrinogen and fibrin structure and functions. J Thromb Haemost 3:1894-1904.
77. Mueller SC, Ghersi G, Akiyama SK, Sang QX, Howard L, Pineiro-Sanchez M, Nakahara H, Yeh Y, Chen WT. 1999. A novel protease-docking function of integrin at invadopodia. J Biol Chem 274:24947-24952.
78. Nash GH, Turner LF, Scully MF, Kakkar AK. 2002. Platelets and cancer. Lancet Oncol 3:425-430.
79. Nomizu M, Yokoyama F, Suzuki N, Okazaki I, Nishi N, Ponce ML, Kleinman HK, Yamamoto Y, Nakagawa S, Mayumi T. 2001. Identification of homologous biologically active sites on the N-terminal domain of laminin alpha chains. Biochemistry 40:15310-15317.
80. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y, Moses M, Lane WS, Sage EH, Folkman J. 1994. Angiostatin: A circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 59:471-482.
81. Odaka C, Tanioka M, Itoh T. 2005. Matrix metalloproteinase-9 in macrophages induces thymic neovascularization following thymocyte apoptosis. J Immunol 174:846-853.
82. Oppenheimer SB. 2006. Cellular basis of cancer metastasis: A review of fundamentals and new advances. Acta Histochem 108:327-334.
83. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. 1997. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
84. Ortega N, Werb Z. 2002. New functional roles for non-collagenous domains of basement membrane collagens. J Cell Sci 115:4201-4214.
85. Ortiz-Urda S, Garcia J, Green CL, Chen L, Lin Q, Veitch DP, Sakai LY, Lee H, Marinkovich MP, Khavari PA. 2005. Type VII collagen is required for ras-driven human epidermal tumorigenesis. Science 307:1773-1776.
86. Page-McCaw A, Ewald AJ, Werb Z. 2007. Matrix metalloproteinases and the regulation of tissue remodeling. Nat Rev Mol Cell Biol 8:221-233.
87. Patarooyo M, Tryggvason K, Virtanen I. 2002. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Caner Biol 12:197-207.
88. Pernasetti F, Nickel J, Clark D, Baeuerle PA, Van Epps D, Freimark B. 2006. Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach. Int J Oncol 29:1371-1379.
89. Petitclerc E, Boutaud A, Prestayko A, Xu J, Sado Y, Ninomiya Y, Sarras MP, Jr., Hudson BG, Brooks PC. 2000. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 275:8051-8061.
90. Pyke C, Romer J, Kallunki P, Lund LR, Ralfkiaer E, Dano K, Tryggvason K. 1994. The gamma 2 chain of kalinin/laminin 5 is peferentially expressed in invading malignant cells in human cancers. Am J Pathol 145:782-791.
91. Ramaswamy S, Ross KN, Lander ES, Golub TR. 2003. A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54.
92. Ramchandran R, Dhanabal M, Volk R, Waterman MJ, Segal M, Lu H, Knebelmann B, Sukhatme VP. 1999. Antiangiogenic activity of restin, NC1 domain of human collagen XV: Comparison to endostatin. Biochem Biophys Res Commun 255:735-739.
93. Ramont L, Brassart-Pasco S, Thevenard J, Deshorgue A, Venteo L, Laronze JY, Pluot M, Monboisse JC, Maquiart FX. 2007. The NC1 domain of type XIX collagen inhibits in vivo melanoma growth. Mol Cancer Ther 6:506-514.
94. Roeb E, Schleinkofer K, Kernebeck T, Pötsch S, Jansen B, Behrmann I, Matern S, Grötzinger J. 2002. The matrix metalloproteinase 9 (MMP-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist. J Biol Chem 277:50326-50332.
95. Roth JM, Akalua A, Zelmanovich A, Policarpio D, Ng B, MacDonald S, Formentin S, Liebes L, Brooks PC. 2005. Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo. Am J Pathol 166:901-911.
96. Roth JM, Cautn M, Cretu A, Akalua A, Policarpio D, Li X, Gagne P, Formenti S, Brooks P. 2006. Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen. Am J Pathol 168:1576-1586.
97. Sakata N, Sasatomi Y, Meng J, Ando S, Uesugi N, Takebayashi S, Nagai R, Horiuchi S. 2000. Possible involvement of altered RGD sequence in reduced adhesive and spreading activities of advanced glycation end product-modified fibronectin to vascular smooth muscle cells. Connect Tissue Res 41:213-228.
98. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, Neri D, Riva P. 2003. Immunoscitigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis in patients with cancer. Clin Can Res 9:571-579.
99. Schenk S, Quaranta V. 2003. Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell Biol 13:366-375.
100. Schenk S, Hintermann E, Bilban M, Koshikawa N, Hojilla C, Khonkha R, Quaranta V. 2003. Binding to EGF receptor of laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol 161:197-209.
101. Seftor EA, Brown KM, Chin L, Kirschmann DA, Wheaton WW, Protopov A, Feng B, Balagurunathan Y, Trent JM, Nickoloff BJ, Seftor RE, Hendrix MJ. 2005. Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment. Cancer Res 65:10164-10169.
102. Seiffer D, Smith JW. 1997. The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem 272:13705-13710.
103. Sidani M, Wyckoff J, Xue C, Segall JE, Condeelis J. 2006. Probing the microenvironment of mammary tumors using multiphoton microscopy. J Mammary Gland Biol Neoplasia 11:151-163.
104. Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA. 2001. Disruption of matrix metalloproteinase 2 binding to integrin alphav beta3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci U S A 98:119-124.
105. Silletti S, Yebra M, Perez B, Cirulli V, McMahon M, Montgomery AM. 2004. Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion. J Biol Chem 279:28880-28888.
106. Smolarczyk K, Boncela J, Szymanski J, Gils A, Cierniewski C. 2005. Fibrinogen contains cryptic PAI-1 binding sites that are exposed on binding to solid surfaces or limited proteolysis. Arterioscler Thromb Vasc Biol 25:2679-2684.
107. Soon L, Braet F, Condeelis J. 2007. Moving in the right direction-nanoimaging in cancer cell motility and metastasis. Microsc Res Tech 70:252-257.
108. Staton CA, Brown NJ, Rodgers GR, Corke KP, Tazzyman S, Underwood JC, Lewis CE. 2004. Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. Blood 103:601-606.
109. Steeg PS. 2006. Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med 12:895-904.
110. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. 2001. Apoptosis of adherent cells by recruitment of caspase-9 to unligated integrins. J Cell Biol 155:459-470.
111. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kallur R. 2003. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A 100:4766-4771.
112. Tomasini BR, Mosher DF. 1988. Conformational states of vitronectin: Preferential expression of an antigenic epitope when vitronectin is covalently and noncovalently complexed with thrombin-antithrombin II or treated with urea. Blood 72:903-912.
113. Uhm JH, Dooley NP, Kyritsis AP, Rao JS, Gladson CL. 1999. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res 5:1587-1594.
114. Wang XQ, Sun P, Paller AS. 2003. Ganglioside GM3 blocks the activation of epidermal growth factor receptor induced by integrin at specific tyrosine sites. J Biol Chem 278:48770-48778.
115. 1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J Cell Biol 164:935-941.
116. Waterman EA, Sakai N, Nguyen NT, Horst BA, Veitch DP, Dey CN, Ortiz-Urda S, Khavari PA, Marinkovich MP. 2007. A laminin-collagen complex drives human epidermal carcinogenesis through phosphoinositol-3-kinase activation. Cancer Res 67:4264-4270.
117. Weidner N. 2002. New paradigm for vessel intravasation by tumor cells. Am J Pathol 160:1937-1939.
118. Wess TJ. 2005. Collagen fibril form and function. Adv Protein Chem 70:341-374.
119. Wikner NE, Clark RA. 1988. Chemotactic fragments of fibronectin. Methods Enzymol 162:214-222.
120. Witz IP, Levy-Nissenbraum O. 2006. The tumor microenvironment in the post-PAGET era. Cancer Lett 242:1-10.
121. Xu J, Rodriguez D, Kim J, Brooks PC. 2000. Generation of monoclonal antibodies to cryptic collagen sites by using subtractive immunization. Hybridoma 19:375-385.
122. Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, Davis GE, Brooks PC. 2001a. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154:1069-1079.
123. Xu R, Yao ZY, Xin L, Zhang Q, Li TP, Gan RB. 2001b. NC1 domain of human type VIII collagen (α1) inhibits bovine aortic endothelial cell proliferation and causes cell apoptosis. Biochem Biophys Res Comm 289:264-268.
124. Yamamura K, Kibbey MC, Kleinman HK. 1993. Melanoma cells selected for adhesion to laminin peptides have different malignant properties. Cancer Res 53:423-428.
125. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. 2004. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927-939.
126. Yi M, Ruoslahti E. 2001. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci U S A 98:620-624.
127. Zhou Z, Doi M, Wang J, Cao R, Liu B, Chan KM, Kortesmaa J, Sorokin L, Cao Y, Tryggvason K. 2004. Deletion of laminin-8 results in increased tumor neovascularization and metastasis in mice. Cancer Res 64:4059-4063.